Reducing chemotherapy dose intensity by 25% and adding rituximab improves survival in pediatric mature B‐cell non‐Hodgkin lymphoma in LMIC setting
Pediatric Blood & Cancer · 2023
DOI: 10.1002/pbc.30694 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pediatric Blood & Cancer, 2023. Verfasst von Venkatraman Radhakrishnan und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical and Pediatric Oncology, Cancer Institute (WIA), Adyar, Chennai, Tamil Nadu, India. Hauptthemen laut MEDLINE: Rituximab, Antineoplastic Combined Chemotherapy Protocols, Lymphoma, B-Cell, Burkitt Lymphoma. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 25 Literaturangaben.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background and objectives Pediatric B‐cell non‐Hodgkin lymphomas (NHL) in low‐ and middle‐income countries (LMICs) have historically had inferior outcomes due to higher treatment‐related mortality (TRM) and relapses. To address this issue, we evaluated the impact of reducing chemotherapy dose intensity by 25% and adding rituximab on outcomes in pediatric B‐NHL. Patients and methods Patients, less than 18 years of age with group B and C disease as per the Lymphome Malin de Burkitt (LMB) risk stratification were enrolled between September 2017 and October 2022. The LMB‐89 protocol, with a 25% reduction in all chemotherapy doses and the addition of rituximab, was administered. The response was assessed using positron emission tomography with computed tomography (PET/CT) after four cycles of chemotherapy (interim) and at the end of treatment.
Results
The study included 25 patients with a median age of 6.9 years, among whom 20 (80%) were males. Twenty patients had group B and five had group C disease. Complete metabolic response (CMR) was achieved by 22/25 (88%) patients, and three (12%) achieved partial metabolic response (PMR) in the interim PET/CT. At the end of treatment, 22/24 (92%) patients achieved CMR, one had PMR, and one had progressive disease. The median follow‐up was 45 months (range: 3–71 months). The 4‐year event‐free survival and overall survival were 88% and 92%, respectively. There were two deaths, one due to disease progression and the other due to sepsis.
Conclusion
Our study demonstrates a significant improvement in outcomes in pediatric B‐NHL compared to previous reports from LMICs, achieved through a 25% reduction in chemotherapy dose intensity and the addition of rituximab.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical and Pediatric Oncology, Cancer Institute (WIA), Adyar, Chennai, Tamil Nadu, India.
ORCID-Profile: Venkatraman Radhakrishnan, Gargi Das, Jaikumar Ramamurthy
Zitieren
APA
Radhakrishnan, V., Kritthivasan, V., Kothandan, B. T., Srinivasan, P., Das, G., & Ramamurthy, J. (2023). Reducing chemotherapy dose intensity by 25% and adding rituximab improves survival in pediatric mature B‐cell non‐Hodgkin lymphoma in LMIC setting. Pediatric Blood & Cancer. https://doi.org/10.1002/pbc.30694
Vancouver
Radhakrishnan V, Kritthivasan V, Kothandan BT, Srinivasan P, Das G, Ramamurthy J. Reducing chemotherapy dose intensity by 25% and adding rituximab improves survival in pediatric mature B‐cell non‐Hodgkin lymphoma in LMIC setting. Pediatric Blood & Cancer. 2023. doi:10.1002/pbc.30694
BibTeX
@article{Radhakrishnan2023,
author = {Radhakrishnan, Venkatraman and Kritthivasan, Venkatakrishnan and Kothandan, Balaji Thiruvengadam and Srinivasan, Prasanth and Das, Gargi and Ramamurthy, Jaikumar},
title = {Reducing chemotherapy dose intensity by 25% and adding rituximab improves survival in pediatric mature B‐cell non‐Hodgkin lymphoma in LMIC setting},
journal = {Pediatric Blood & Cancer},
year = {2023},
doi = {10.1002/pbc.30694}
}
EUVIMED